about
G Protein-Coupled Receptors in CancerNiacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation.Teaching old receptors new tricks: biasing seven-transmembrane receptors.Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment.Niacin: another look at an underutilized lipid-lowering medication.Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue.Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parametersRetinal transfer of nicotinate by H+ -monocarboxylate transporter at the inner blood-retinal barrier.Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.G Protein-coupled Receptor Biased Agonism.Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptorsUse of nicotinamide to treat hyperphosphatemia in dialysis patients.Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.Niacin, an old drug with new perspectives for the management of dyslipidaemia.Pharmacotherapy of dyslipidemias in the adult population.Endogenous metabolites as ligands for G protein-coupled receptors modulating risk factors for metabolic and cardiovascular disease.Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.Distinct kinetic and spatial patterns of protein kinase C (PKC)- and epidermal growth factor receptor (EGFR)-dependent activation of extracellular signal-regulated kinases 1 and 2 by human nicotinic acid receptor GPR109A.Antibacterial Activity and Cytotoxicity of Silver(I) Complexes of Pyridine and (Benz)Imidazole Derivatives. X-ray Crystal Structure of [Ag(2,6-di(CH2OH)py)2]NO3.Crystal structure of human nicotinic acid phosphoribosyltransferase.Design, synthesis and biological evaluation of some 2-azetidinone derivatives as potential antihyperlipidemic agents.Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs.Lowering Expectations with Niacin Treatment for CKD-MBD.A promising codrug of nicotinic acid and ibuprofen for managing dyslipidemia. I: synthesis and in vitro evaluation.Chicken Is a Useful Model to Investigate the Role of Adipokines in Metabolic and Reproductive Diseases.
P2860
Q26741203-899B1E1A-AEEF-40C5-BAAC-57E90F53660FQ33625837-BC9C65A6-ED54-40A8-8536-E55DD3E6BFB9Q33985759-3365BFB0-17E4-4A60-B590-CC325FA91409Q34028556-00F32C60-AA7D-4687-975C-7F332CCC87C3Q34255686-CBC28C59-AA86-431F-AB07-738DD4208C4CQ34368772-60A3799B-539C-43A9-BF69-9BFA65D2B9E1Q35055437-0868CC6A-784F-48B2-9469-22B733CF4A82Q35432791-270050C0-F5A2-4BCE-B3D8-972C28822D43Q35440499-20C9019F-96FB-4A39-AE73-E0747B3F5059Q35575652-645E0BA0-132F-4A04-A583-1A3D03A5E88FQ35858061-20E9D548-C533-4541-B453-B64CF0B6E467Q35895434-565880B3-24C4-469B-8649-6DF2CF11FF30Q36419283-6D7F05DC-DCB5-418E-A559-8D0790DDF77FQ36665235-8BA3901D-72B6-459C-A32A-FE4C180FD4BEQ36773326-9B32AD76-8EC7-4762-9FAA-5CF852FDBBAEQ37199788-36CC97DA-D9B7-4ACB-A8D4-5C83150C1BE0Q37376937-1FA370D5-9824-404F-A862-86E744E0A719Q37667487-4944851A-521B-46D3-B7F5-3B1FEB53BAD4Q37725868-13151C7B-FDE8-463E-8BFB-0A4993AB48EBQ37801374-B9E46952-7C5E-4708-B1AF-75CAD1CEDE99Q38067511-8B7D3BB9-E0EC-4BE3-86F2-DFB032C08482Q38384208-30EA900C-C3C9-4014-B2F8-363B1A79DF8BQ38418432-E8DA5807-A414-44D8-94BA-870DBB0C6FA0Q38797866-4415E1ED-AABA-45EC-8D41-030340D59D10Q40870579-83073795-0810-40ED-BEBC-DE4264931836Q43905945-784BF0A8-A735-4388-AB44-B6E133BF761DQ48526234-D9D33415-6664-4B62-9A50-A66334AA54E4Q50059026-A3B76A4B-799E-4C84-BC80-850E13B24231Q51592860-1FDDABC6-6286-4CCE-80AC-68A24CF404CFQ55690183-42CDF1A4-76DE-49A9-BC0A-927857914A89
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Nicotinic acid: an old drug with a promising future
@ast
Nicotinic acid: an old drug with a promising future
@en
type
label
Nicotinic acid: an old drug with a promising future
@ast
Nicotinic acid: an old drug with a promising future
@en
prefLabel
Nicotinic acid: an old drug with a promising future
@ast
Nicotinic acid: an old drug with a promising future
@en
P2860
P356
P1476
Nicotinic acid: an old drug with a promising future
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0707528
P407
P478
153 Suppl 1
P577
2007-11-26T00:00:00Z